** Indian drugmaker Sun Pharmaceutical Industries SUN.NS posted 26.2% y/y jump in Q4 profit, aided by strong demand for its specialty drugs
** Shares of SUN fall ~0.9%
STEADY GROWTH, BUT NEAR-TERM PRESSURE
** HDFC Securities ("Buy," PT: 2,120 rupees) sees continued strength in specialty drugs and India business, supported by key brands and new launches
** Emkay ("Add," PT: 2,000 rupees) says Organon turnaround may depend on external factors, adding the stock could see a pause in gains near PT
** Ambit ("Buy," PT: 2,100) says business is at an inflection point, with growth likely to pick up as branded and innovative medicines scale up
** Elara Securities ("Accumulate," PT: 2,085 rupees) cuts FY27 earnings on lower margin assumptions, citing slower ramp-up in key U.S. innovative products and tariff risks
(Reporting by Bipasha Dey in Bengaluru)
((Bipasha.Dey@thomsonreuters.com;))